We found, on average, 63 and eight significantly regulated enzymes and biosynthetic pathways, respectively, across cancers, suggesting a widespread dysregulation of GPCR-ligand biosynthetic pathways in human malignancies, which in some cases was specific to distinct cancer subtypes (Figure 3A). This evidence concerns the gene LGR6 and cancer.